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ABSTRACT 
Hypoxia is a common characteristic of hepatocellular carcinoma (HCC) associated with reduced response to 
chemotherapy, thus increasing the probability of tumor recurrence. Astrocyte elevated gene-1 (AEG-1) has been 
involved in a wide array of cancer progression including proliferation, chemoresistance, angiogenesis and metas-
tasis, but its effect on HCC chemoresistance induced by hypoxia is unclear. In this study, expression of AEG-1 
and multiple drug resistance (MDR-1) were examined in HCC using immunohistochemical staining and RT-
PCR. Furthermore, their expression levels were detected in HCC HepG2 cells in normoxia or hypoxia via RT-
PCR and Western blot assays. Specific shRNAs were used to silence AEG-1 expression in HepG2 cells. Results 
showed AEG-1 and MDR-1 expression were higher in HCC tissues than in adjacent normal tissues. Incubation 
of HepG2 cells in hypoxia increased expression of AEG-1 and MDR-1, compared to incubation in normoxia. 
Exposure to hypoxia blunted sensitivity of HepG2 cells to Adriamycin, 5-fluorouracil and cis-platinum, as evi-
denced by modest alterations in cell viability and apoptosis rate, however the sensitivity was elevated with AEG-
1 knockdown. PI3K/AKT/HIF-1/MDR-1 pathway was attenuated following AEG-1 knockdown in hypoxia. 
Based on these data, it was suggested that AEG-1 is associated with hypoxia-induced hepatocellular carcinoma 
chemoresistance via regulating PI3K/AKT/HIF-1/MDR-1 pathway. This study uncovered a novel potential tar-
get for development of an effective therapy against hypoxia-induced HCC chemoresistance. 
 
Keywords: AEG-1, hypoxia, hepatocellular carcinoma, chemoresistance, PI3K/AKT/HIF-1/MDR-1 pathway 
 
 
 
INTRODUCTION 
Hepatocellular carcinoma (HCC) is a 
frequently occurring primary cancer, repre-
senting one of the leading cause of cancer-
related deaths worldwide (Xu et al., 2014). 
Of note, HCC has very high prevalence in 
China occupying half of the cases and deaths 
(Xu et al., 2014). The Cancer Country Pro-
files from World Health Organization esti-
mated that 394,770 of new liver cancer cases 
and 380,772 cancer deaths were occurred in 
China only in 2014 (Zhang et al., 2016). 
Chemotherapeutic regimens remain the 
treatment of choice for hepatocellular carci-
noma especially at the advanced stages. An-
ti-cancer agents including Adriamycin 
(ADM), 5-fluorouracil (5-FU) and cis-
platinum (DDP) are commonly used in the 
prescriptions to HCC patients in China due 
to their inexpensive price and easy accessi-
bility (Lia et al., 2016). But these chemother-
apy options ultimately yield poor outcomes 
in these patients mainly resulted from the 
chemoresistant development of HCC.  
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It has been identified that the hypoxic 
tumor microenvironment plays a prominent 
role in the induction of chemoresistance. 
Hypoxia is a common characteristic of HCC 
and other solid tumors (Zhang et al., 2016). 
Rapid growth of tumors easily leads to insuf-
ficient blood supply in the central region of 
the tumor (Bogaerts et al., 2015). When tu-
mor cells are located further than 100-
180 μm from a functional blood vessel, oxy-
gen is difficult to diffuse beyond this dis-
tance (Flamant et al., 2012). Besides, fibro-
genesis during the development of cirrhosis 
destroys the normal blood supply to both 
normal liver tissues and HCC, which can 
lead to local hypoxia (Bogaerts et al., 2015). 
Hypoxic environment triggers a variety of 
adaptive responses in HCC to survival in 
harsh conditions, and it provides a strong se-
lective pressure for the survival of HCC, 
which results in the so called “survival of the 
fittest” and elimination of the inferior (Zhang 
et al., 2016; Flamant et al., 2012; Bogaerts et 
al., 2015). Significant evidence indicates that 
HCC cells that are survival in hypoxia are 
more resistant to chemotherapy than the cells 
growing in normoxia (Zhang et al., 2016; 
Flamant et al., 2012; Bogaerts et al., 2015). 
A few of signaling molecules are activated 
by hypoxia and are responsible for the 
chemoresistance.  
Transcriptional factor hypoxia-inducible 
factor 1 (HIF-1) is a master regulator upon 
hypoxia. HIF-1 is rapidly degraded by pro-
teasome pathway under normoxia, but it be-
comes stable under hypoxia and translocates 
to the nucleus controlling its target genes via 
binds to hypoxia response elements (Suhara 
et al., 2015). As a target of HIF-1, WSB-1 
is a key protein involved in DNA damage re-
sponse (Tong et al., 2013). HIF-1 suppress-
es etoposide-induced cell death in hypoxic 
HCC cells via regulating WSB-1 (Tong et 
al., 2013). Suppression of the accumulation 
and activity of HIF-1 reversely sensitizes 
HCC to anti-tumor agents, like camptothecin 
and sorafenib (Cai et al., 2014). Besides, it is 
found that HIF-1α/MDR-1 (multiple drug re-
sistance) pathway confers chemoresistance 
to cisplatin in bladder cancer and to doxoru-
bicin in breast cancer upon hypoxic envi-
ronment (Doublier et al., 2012; Li et al., 
2015a; Sun et al., 2016). MDR-1 is closely 
linked to drug resistance through pumping 
out extensively anti-cancer drugs from can-
cer cells (Hyuga et al., 2012). These data in-
dicate HIF-1 functions as an essential regu-
lator leading to the development of tumor 
chemoresistance in hypoxia. Under hypoxic 
conditions, the serine/threonine kinase Akt is 
also activated in a wide variety of cancers 
and involved in mechanisms underlying hy-
poxia-induced chemoresistance (Lau et al., 
2009). AKT acts as a nexus-signaling mole-
cule in the phosphatidylinositol 3-kinase 
(PI3K)/AKT pathway that is implicated in 
the regulation of HIF-1 transcriptional ac-
tivity (Lau et al., 2009). In a HCC xenograft 
model, blockage of PI3K/AKT/HIF-1 sig-
naling enforces the therapeutic efficacy of 
hypoxic chemotherapy (Jiao and Nan, 2012).  
Astrocyte elevated gene-1 (AEG-1) was 
originally cloned as neuropathology-
associated gene in primary human embryos 
astrocytes in 2002 (Su et al., 2002). Further 
research reveals the dominant role in the de-
velopment and progression of diverse can-
cers (Meng et al., 2013; Chang et al., 2016). 
AEG-1 as a multi-functional protein has 
been involved in a wide array of cancer pro-
gression including pro-survival, chemo-
resistance, angiogenesis and metastasis, via 
interaction with multiple oncogenic signaling 
pathways (Meng et al., 2013; Chang et al., 
2016). As for the modulation of chemo-
resistance, AEG-1 overexpression has been 
associated with cisplatin resistance in pa-
tients with stage III–IV serous ovarian carci-
noma and the poor prognosis (Li et al., 
2012). However, it is unclear whether AEG-
1 participates in the promoting effects of hy-
poxia on HCC chemoresistance. A close as-
sociation of AEG-1 with PI3K/AKT path-
way has been unveiled in numerous studies 
(Meng et al., 2013). It has been confirmed 
that AEG-1 is a downstream target of 
PI3K/AKT signal because induction of 
AEG-1 was attenuated by treatment with the 
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PI3K inhibitor LY294002 or overexpression 
of phosphatase and tensin homolog (PTEN) 
that is well-known for its inhibitory effects 
on PI3K/AKT signal (Lee et al., 2006). But, 
PI3K/AKT signal is also under the regulation 
of AEG-1. It was reported that AEG-1 over-
expression inhibits serum starvation-induced 
apoptosis by activating the PI3K/AKT sig-
naling pathway (Lee et al., 2006). AEG-1 
was found to physically interact with AKT2, 
resulting in activation of AKT signal and ag-
gression of glioblastoma (Emdad et al., 
2015). Through controlling PI3K/AKT sig-
nal, AEG-1 is probably implicated in the 
regulation of HIF-1α/MDR-1 and hypoxia-
induced HCC chemoresistance. Our study 
herein confirmed that AEG-1 represents a 
propitious therapeutic target for counteract-
ing hypoxia-induced HCC chemoresistance.  
 
MATERIALS AND METHODS 
Tissue samples and immunohistochemical 
staining 
22 pairs of HCC and adjacent normal tis-
sues were obtained from patients, who expe-
rienced surgery at the Third Xiangya Hospi-
tal of Central South University. The tissues 
were either embedded in paraffin or placed 
in liquid nitrogen based on different detec-
tions. All patients provided written informed 
consent. The study was approved by the Eth-
ics Committee of the Third Xiangya Hospital 
of Central South University and followed the 
Declaration of Helsinki. 
AEG-1 and MDR-1 expression were ex-
amined in the paraffin-embedded specimens 
using immunohistochemistry. Tissue sec-
tions were dewaxed in xylene and rehydrated 
using standard procedures. After they were 
washed in phosphate-buffered saline (PBS) 
three times for 5 minutes each, antigen re-
trieval was undertaken using a pressure 
cooker at 121 °C for 15 min in 0.01 M citrate 
buffer (pH 6.0). To block any potential non-
specific binding of the secondary antibody, 
sections were incubated in 10 % normal goat 
serum for 30 min at room temperature. The 
slides were incubated with a primary anti-
body against human AEG-1 (dilution 1:200; 
ab76742, Abcam, Cambridge, UK) and 
MDR-1 (dilution 1:200; sc-71557, Santa 
Cruz Biotechnology Inc., CA, USA) over-
night at 4 °C. After the slides were washed 
with PBS, the sections were incubated with a 
biotin-labeled secondary antibody (Santa 
Cruz Biotechnology Inc.). Finally, sections 
were lightly counterstained using hematoxy-
lin. 
 
Cell culture and treatments 
The human HCC HepG2 cells were pur-
chased from the American Type Culture Col-
lection (ATCC, Manassas, VA, USA). 
HepG2 cells were maintained in RPMI-1640 
medium/DMEM (Hyclone Laboratories Inc., 
Logan, Utah, USA) supplemented with 10 % 
fetal bovine serum (Hyclone) and 1 % peni-
cillin-streptomycin in a humidified atmos-
phere of 5 % CO2 at 37 °C. The culture me-
dium was replaced every 3 days.  
Hypoxia treatment was carried out by 
placing the cells in a sealed chamber (Ther-
mo Forma) filled with mixture gases of 1 % 
O2, 5 % CO2, and 94 % N2. HepG2 cells 
were incubated under normoxia or hypoxia 
for 0, 24, 48 and 72 h, before detection of the 
mRNA and protein expression levels of 
AEG-1 and MDR-1. To get insight into the 
regulatory role of AEG-1 in chemoresistance 
of HCC under hypoxia, AEG-1 expression 
was silenced in HepG2 cells by transfection 
with specific shRNA. HepG2 cells with 
AEG-1 knockdown or not were incubated 
with doses of ADM, 5-FU and DDP under 
normoxia or hypoxia for different periods of 
time. Cell viability and apoptosis assays 
were conducted to evaluated impact of 
down-regulated AEG-1 on HCC chemo-
resistance.  
 
Quantitative real-time reverse transcription 
polymerase chain reaction (RT-PCR) assay 
The HCC and adjacent normal tissue 
samples were retrieved from liquid nitrogen 
and grinded to tiny particles, before incuba-
tion with TRIzol (Takara, Otsu, Shiga, Ja-
pan) to isolated mRNA. HepG2 cells that 
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were harvested in 35 mm dishes were also 
incubated with TRIzol (Takara) to extract 
mRNA. 500 ng RNA was applied to synthe-
sis first-strand complementary DNA using 
first-strand cDNA Synthesis Kit (Takara, 
Otsu, Shiga, Japan). RT-PCR was performed 
in a mixture composed of SYBR Green 
(Takara), 1 μl (0.2 μmol/l) of each primer, 
and 1.6 μl of complementary DNA from RT-
PCR samples. The primer sequences were as 
follows: AEG-1, 5’-CGGTACCCCGGCTG 
GGTGAT-3’ (forward) and 5’-CTCCTCCG 
CTTTTTGCGGGC-3’ (reverse); MDR-1, 
5’-GCCGGGAGCAGTC ATCTGTGG-3’ 
(forward) and 5’-ATCCAT TCCGACCTC 
GCGCT-3’ (reverse); GAP DH, 5’-CAAT 
GACCCCTTCATTGACC-3’ (forward) and 
5’-GACAAGCTTCCCGTTC TCAG-3’ (re-
verse). The mRNA levels of AEG-1 and 
MDR-1 were quantified by the Ct values, 
and GAPDH was set as an internal control.  
Experiments were performed in tripli-
cate. The relative expression levels were 
evaluated using the -ΔΔCt method as de-
scribed previously (Yang et al., 2014). Each 
individual experiment was performed three 
times independently. 
 
Western blot assay 
Total proteins were extracted from the 
HepG2 cells with RIPA buffer containing 
proteinase/phosphatase inhibitors (Thermo, 
Cambridge, MA). Proteins were separated on 
a 10 % or 12 % SDS-PAGE gel, and then 
transferred onto a nitrocellulose membrane 
(Millipore, Bedford, MA). The membranes 
were incubated with one of the following an-
tibodies: anti-AEG-1 antibody (1:500; 
ab45338, Abcam), anti-MDR-1 antibody 
(1:500; sc-5510, Santa Cruz Biotechnology 
Inc.), anti-PI3K antibody (1:500; ab22653, 
Abcam), anti-AKT antibody (1:600; #21054, 
SAB, Shanghai, China), anti-HIF-1α anti-
body (1:1000; sc-10790, Santa Cruz Bio-
technology Inc.), anti-PTEN antibody 
(1:500; sc-6818, Santa Cruz Biotechnology 
Inc.) and anti-GAPDH antibody (1:800; sc-
365062, Santa Cruz Biotechnology Inc.). Af-
ter washing, the membranes were incubated 
with horseradish peroxidase-conjugated sec-
ondary antibodies that target mouse IgG 
(ab97040, Abcam), rabbit IgG (A0545, Sig-
ma, St Louis, MO, USA), or goat IgG 
(A5420, Sigma) at a 1:2,000 dilution for 2 h 
at room temperature. Reactive proteins were 
detected using Pierce Enhanced Chemi-
luminscent and SuperSignal™ Chemilumi-
nescent substrates (Thermo Fisher Scientific, 
Inc., Waltham, MA, USA).  
 
shRNA knockdown of AEG-1 
Three shRNAs (shRNA-746, shRNA-
1490 and shRNA-1576) targeting AEG-1 
were purchased from GenePharma Co., Ltd 
(Shanghai, China). Transfection of shRNAs 
and scrambled siRNA into HepG2 cells were 
performed using Lipofectamine 2000 (Invi-
trogen, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. RT-PCR, West-
ern blot analysis and an Olympus Fluorview 
1000 confocal microscope were used to se-
lect clones with stable knockdown of AEG-
1.  
 
Cell viability assay 
HepG2 cells were seeded in 96-well 
plates in 100 μL complete medium and al-
lowed to attach overnight. After cells were 
subjected to different treatments, cell viabil-
ity was measured using 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT) assay. MTT (20 ml) solution 
was added into wells of 96-well plates for 
1 h at 37 °C. Absorbance was recorded at 
490 nm using a microplate reader (Bio-Rad, 
Richmond, CA).  
 
Apoptosis assay by flow cytometry 
After subjected to different treatments, 
HepG2 cells were washed and then stained 
with FITC-conjugated Annexin V and PI 
(Clontech, Beijing, China) at room tempera-
ture for 15 min in the dark. The cells were 
collected and analyzed by a FACSCanto II 
flow cytometer (Becton Dickinson Immuno-
cytometry System).  
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Statistics 
All values are expressed as mean ± 
SEM. Differences between groups were ana-
lyzed by one-way ANOVA with SPSS 13.0 
(IBM, Armonk, NY, USA), followed by 
Bonferroni post-hoc analyses as appropriate. 
Graphs were generated with Excel. P < 0.05 
was denoted as statistically significant. 
 
RESULTS 
AEG-1 and MDR-1 expression in HCC and 
adjacent normal tissues 
AEG-1 and MDR-1 expression in HCC 
and adjacent normal tissues were investigat-
ed by immunohistochemical staining and 
RT-PCR assays. Figure 1A shows the repre-
sentative pictures in immunohistochemical 
staining assay. It was observed that AEG-1 
and MDR-1 were expressed in cytoplasm in 
normal liver tissues. Similarly, HCC tissues 
exhibited AEG-1 and MDR-1 expression in 
cytoplasm. RT-PCR is a useful approach to 
quantify mRNA expression of targeted 
genes. With this method, AEG-1 and MDR-1 
were found to be up-regulated in HCC tis-
sues compared to adjacent normal tissues (P 
= 0.023 and P = 0.039 respectively, Figure 
1B).  
 
Hypoxia triggered up-regulation of AEG-1 
and MDR-1 in HCC cells  
To understand the roles of AEG-1 and 
MDR-1 in hypoxia-induced chemoresistance 
in HCC, we initially detected AEG-1 and 
MDR-1 expression under hypoxic environ-
ment via RT-PCR and Western blot assays. 
HCC HepG2 cells were incubated under 
normoxia or hypoxia for 0, 24, 48 and 72 h, 
before detection of the mRNA and protein 
expression levels of AEG-1 and MDR-1. As 
Figure 2A noted, mRNA expression of 
AEG-1 was higher in hypoxia than in 
normoxia at time points of 24 (P = 0.038), 
48 (P = 0.03) and 72 h (P = 0.036). Similar-
ly, MDR-1 showed higher mRNA expression 
in hypoxia for 24 (P = 0.042), 48 (P = 0.031) 
and 72 h (P = 0.035) compared to that in 
normoxia. Reflected by Western blotting, 
  
 
Figure 1: AEG-1 and MDR-1 expression in HCC and adjacent normal tissues 
AEG-1 and MDR-1 expression in HCC and adjacent normal tissues were investigated by immuno-
histochemical staining (A) and RT-PCR assays (B). AEG-1: Astrocyte elevated gene-1; MDR-1: multi-
ple drug resistance gene-1; Cancer: Hepatocellular carcinoma; Normal: matched adjacent normal liver 
tissues. *P < 0.05 vs. control, n = 22. 
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AEG-1 showed higher protein expression 
level in hypoxia than in normoxia at time 
points of 24 (P = 0.033, Figure 2B), 48 (P = 
0.026) and 72 h (P = 0.037). Incubation of 
HepG2 cells in hypoxia for 24 (P = 0.035), 
48 (P = 0.027) and 72 h (P = 0.031) resulted 
in higher MDR-1 protein level compared that 
in normoxia. 
 
Knocking down AEG-1 expression in 
HepG2 cells 
To silence AEG-1 expression in HepG2 
cells, the cells were transfected with three 
shRNAs (shRNA-746, shRNA-1490 and 
shRNA-1576) that specifically target AEG-
1. Then the cells were incubated under hy-
poxia for 48 h. Results obtained from RT-
PCR assay showed that shRNA-746 had the 
strongest inhibitory effect on AEG-1 mRNA 
level (P = 0.017 vs. control, Figure 3A) 
compared with other shRNAs. Western blot 
assay indicated that shRNA-746 attenuated 
AEG-1 protein expression to the lowest level 
among all these shRNAs (P = 0.019 vs. con-
trol, Figure 3B). shRNA-746 was thus used 
in further study. 
AEG-1 knockdown enhanced responses of 
HepG2 cells to ADM, 5-FU and DDP under 
hypoxia 
HepG2 cells with AEG-1 knockdown or 
not were incubated with doses of ADM, 5-
FU and DDP under normoxia or hypoxia for 
different periods of time. Variation curves of 
cell viability, determined by MTT assay, af-
ter the treatments were presented in Figure 4. 
It was observed that ADM dose-dependently 
decreased HepG2 cell viability after the in-
cubation under normoxia for 24, 48 and 72 h. 
In contrast, incubation in hypoxia for differ-
ent periods of time (24, 48 and 72 h) attenu-
ated cytotoxic effect of ADM at all treated 
dosages. But, AEG-1 knockdown to certain 
extent reversed cytotoxic effect of ADM on 
HepG2 cells in hypoxia. Hypoxic environ-
ment also inhibited cytotoxic effects of 5-FU 
and DDP, but depletion of AEG-1 enhanced 
their effects in hypoxia.  
 
 
 
 
Figure 2: Hypoxia triggered up-regulation of AEG-1 and MDR-1 in HCC cells  
HCC HepG2 cells were incubated under normoxia or hypoxia for 0, 24, 48 and 72 h, before detection 
of the mRNA (A) and protein expression (B) levels of AEG-1 and MDR-1. AEG-1: Astrocyte elevated 
gene-1; MDR-1: multiple drug resistance gene-1; NO: normoxia; LO: low oxygen. *P < 0.05 vs. control, 
n = 4.  
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Figure 3: Knocking down AEG-1 expression in HepG2 cells 
HepG2 cells were transfected with three shRNAs (shRNA-746, shRNA-1490 and shRNA-1576) that 
specifically target AEG-1 to silence AEG-1 expression. Then the cells were incubated under hypoxia 
for 48 h. Results obtained from RT-PCR (A) and Western blot (B) assays showed that shRNA-746 
had the strongest inhibitory effect on AEG-1 expression level. AEG-1: Astrocyte elevated gene-1. *P < 
0.05 vs. control, n = 4. 
 
 
 
Apoptosis assay demonstrated that apop-
tosis rate of HepG2 cells was not altered af-
ter culture in hypoxia for 24 or 48 h, com-
pared to apoptosis rate of HepG2 cells cul-
tured in normoxia (Figure 5). However, 
HepG2 cells with AEG-1 knockdown 
showed dramatically elevated apoptosis rate 
following incubation in hypoxia for 24 (P = 
0.027) or 48 h (P = 0.019). Incubation in hy-
poxia for 24 (P = 0.034) or 48 h (P = 0.029) 
significantly inhibited the apoptosis that in-
duced by 200 ng/ml ADM, compare to incu-
bation in normoxia (Figure 6). AEG-1 
knockdown in HepG2 cells abolished the 
apoptosis-inhibitory effect induced by hy-
poxia. Incubation in hypoxia for 24 (P = 
0.039) or 48 h (P = 0.033) also resulted in 
remark reduction in the apoptosis rate trig-
gered by 50 μg/ml 5-FU, while this inhibito-
ry effect on apoptosis was abrogated with 
AEG-1 depletion. Apoptotic response in-
duced by 25 μg/ml DDP was blunted with 
HepG2 incubated in hypoxia for 24 (P = 
0.017) or 48 h (P = 0.024). Silencing AEG-1 
to some extent recovered the sensitivity of 
HepG2 to DDP in hypoxia for 24 (P > 0.05) 
or 48 h (P = 0.041).  
 
PI3K/AKT/HIF-1/MDR-1 signaling 
pathway was regulated by AEG-1 
Previous researches document that sig-
naling pathway mediated by PI3K/AKT/ 
HIF-1/MDR-1 plays critical role in hypox-
ia-induced chemoresistance. To determine 
whether these signaling molecules are regu-
lated by AEG-1 in hypoxia, we knocked 
AEG-1 down and evaluated their protein ex-
pression after incubation of the cells in hy-
poxia for 48 h. AEG-1 depletion resulted in 
dramatic reduction in protein expression of 
PI3K (P = 0.042), AKT(P = 0.038), HIF-1 
(P = 0.043) and MDR-1 (P = 0.034), while 
PTEN expression (P = 0.028) was increased 
with AEG-1 knockdown (Figure 7). It indi-
cates PI3K/AKT/HIF-1/MDR-1 pathway is 
positively regulated by AEG-1.  
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Figure 4: AEG-1 knockdown enhanced cytotoxicity of ADM, 5-FU and DDP to HepG2 cells un-
der hypoxia 
HepG2 cells with AEG-1 knockdown or not were incubated with doses of ADM, 5-FU and DDP under 
normoxia or hypoxia for different periods of time. Cell viability was determined by MTT assay. ADM: 
Adriamycin; 5-FU: 5-fluorouracil; DDP: cis-platinum; AEG-1: Astrocyte elevated gene-1; NO: normoxia; 
LO: low oxygen; LO + T(-): HepG2 cells transfected with scrambled siRNA were incubated in hypoxia; 
LO + T(+) : HepG2 cells transfected with shRNA-746 were incubated in hypoxia.  
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Figure 5: AEG-1 knockdown increased apoptosis rate of HepG2 in hypoxia 
HepG2 cells with AEG-1 knockdown or not were incubated in hypoxia for 24 or 48 h, before apoptosis 
rate dectection via flow cytometry. Apoptosis rate of HepG2 cells was not altered after culture in hy-
poxia for 24 or 48 h, compared to apoptosis rate of the cells cultured in normoxia. However, HepG2 
cells with AEG-1 knockdown showed dramatically elevated apoptosis rate following incubation in hy-
poxia for 24 and 48 h. NO: normoxia; LO: low oxygen; LO + T(+) : HepG2 cells transfected with 
shRNA-746 were incubated in hypoxia. *P < 0.05 and #P < 0.05 vs. NO, n = 4. 
 
 
DISCUSSION 
AEG-1 has been verified to be up-
regulated in HCC and associated with the 
development and progression (Yoo et al., 
2009; Robertson et al., 2015). AEG-1 is up-
regulated in various HCC cell lines com-
pared to the normal counterparts (Ma et al., 
2014). HCC tissue samples also have higher 
AEG-1 expression than normal liver sam-
ples, as demonstrated by the present study. 
Importantly, AEG-1 expression in HCC is 
increased with the stages from I to IV as 
well as grades of the differentiation from 
well differentiated to poorly differentiated, 
which suggests AEG-1 is positively correlat-
ed with HCC development and metastasis 
(Ahn et al., 2013; Li et al., 2015b). Study 
performed in transgenic mice showed that 
the hepatocyte-specific expression of AEG-1 
give rise to the generation of multinodular 
HCC with steatotic features following treat-
ment with N-nitrosodiethylamine, but this 
event was not observed in wild type mice 
(Srivastava et al., 2012). Hepatocytes isolat-
ed from the AEG-1 transgenic mice exhibit-
ed profound resistance to cell death induced 
by DNA damage, growth factor deprivation 
and chemotherapeutics (Srivastava et al., 
2012). Microarray analysis indicates that 
AEG-1 is involved in the regulation of genes 
associated with proliferation, invasion, me-
tastasis, chemoresistance, angiogenesis and 
senescence (Meng et al., 2013).  
Although AEG-1 serves as an important 
cancer promoter in HCC, but its effect on 
modulation of chemoresistance in hypoxia is 
not understood. Hypoxia is a common event 
in HCC and other solid tumors, due to rapid 
growth of tumor cells that outstrips its vascu-
lature as well as structural and functional ab-
normality of newly formed intra-tumoral 
vessels (Flamant et al., 2012; Bogaerts et al., 
2015). Evidence is mounting that HCC in 
hypoxic regions harbors strong resistance to 
multiple cytotoxic agents, which presents a 
clinical challenge in chemotherapy (Zhang et 
al., 2016; Flamant et al., 2012; Bogaerts et 
al., 2015). Study, herein, also demonstrated 
that hypoxia blunted responses of HCC 
HepG2 cells to ADM, 5-FU and DDP, as ev-
idenced by cell viability and apoptosis as-
says. In addition, the present study for the 
first time found that AEG-1 expression in 
HepG2 cells was increased in hypoxia when 
compared to that in normoxic circumstance; 
deletion of AEG-1 via shRNA interference 
enhanced the sensitivity of HepG2 cells to 
these agents in hypoxia, which indicates that 
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Figure 6: AEG-1 knockdown enhanced apoptosis-induced ability of ADM, 5-FU and DDP to 
HepG2 cells in hypoxia 
HepG2 cells with AEG-1 knockdown or not were incubated with 200 ng/ml ADM, 50 μg/ml 5-FU, or 
25 μg/ml DDP in hypoxia for 24 or 48 h, before apoptosis rate dectection via flow cytometry. NO: 
normoxia; LO: low oxygen; LO + T(+) : HepG2 cells transfected with shRNA-746 were incubated in 
hypoxia. *P < 0.05 and #P < 0.05 vs. NO, n = 4. 
 
 
AEG-1 functions as an important mediator 
responsible for chemoresistance of HepG2 
cells in hypoxia.  
Numerous studies have established the 
functional role of MDR-1 in tumor chemo-
resistance (Hyuga et al., 2012). MDR-1 be-
longs to the ATP-binding cassette (ABC)-
transporter family and contributes to multi-
drug resistance through the efflux of a wide 
range of chemotherapeutic drugs from cancer 
cells (Hyuga et al., 2012). MDR-1 over-
expression is commonly associated with a 
low chemotherapeutic efficiency and poor 
prognosis of cancers, while downregulation 
of MDR-1 expression is an effective way to 
enhance the chemosensitivity of cancer cells 
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Figure 7: PI3K/AKT/HIF-1/MDR-1 signaling pathway was regulated by AEG-1 
HepG2 cells with AEG-1 knockdown or not were incubated in hypoxia for 48h, followed by examina-
tion of protein expression levels of PI3K, AKT, HIF-1, PTEN, and MDR-1 via Western blot assay. 
HIF-1:hypoxia-inducible factor 1; PTEN: phosphatase and tensin homolog; PI3K: phosphatidylinositol 
3-kinase; MDR-1: multiple drug resistance gene-1. Proteins were separated on a 12% SDS-PAGE gel, 
excepted for MDR-1 detection that the proteins were separated on a 10% SDS-PAGE gel. LO: low ox-
ygen; LO + T(+) : HepG2 cells transfected with shRNA-746 were incubated in hypoxia. *P < 0.05 vs. 
LO, n = 4.  
 
 
 
to conventional chemotherapeutic agents. 
Mounting evidence indicates that hypoxia is 
an important incentive factor for MDR-1 ex-
pression. Yang et al. (2016) showed MDR-1 
expression is up-regulated in colorectal can-
cer LOVO cells in CoCl₂-induced hypoxia 
(Yang et al., 2016). In addition, MDR-1 ex-
pression in laryngeal cancer cells is in-
creased following exposure to hypoxic envi-
ronment (Li et al., 2016b). Herein, we ob-
served that incubation of HCC cells in hy-
poxia also gave rise to up-regulation of 
MDR-1 in both mRNA and protein levels, 
thus we suggested that MDR-1 regulation 
mediated the actions of hypoxia-induced 
chemoresistance.  
Bioactivities of HIF-1 are related to the 
oxygen concentration in surrounding envi-
ronment and relevant signaling pathway. 
Hypoxia has been identified as a predomi-
nant cause to HIF-1 activation (Li et al., 
2015a). Since HIF-1 is a key up-stream 
modulator of MDR-1, it is easy to under-
stand that MDR-1 expression was raised un-
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der hypoxia (Zhan et al., 2015). HIF-1 
abundance and activity are also regulated by 
PI3K/AKT signaling pathway. Considering 
there is a crosstalk between AEG-1 and 
PI3K/AKT signal, we hypothetise that AEG-
1 may be implicated in the regulation of 
HIF-1 and its downstream target MDR-1 
(Jiao and Nan, 2012). The present study 
showed that PI3K and AKT expression were 
down-regulated with AEG-1 knockdown, but 
their inhibitor, PTEN, was up-regulated. It 
indicates that AEG-1 exerts promoting ef-
fects on PI3K/AKT signal in hypoxic HCC 
cells. As we expected, attenuated PI3K/AKT 
signal that was resulted from AEG-1 deple-
tion resulted in inhibition of HIF-1/MDR-1 
pathway, thus it is suggested that AEG-1 
positively modulated MDR-1 expression in 
hypoxic HCC via the stimulation of PI3K/ 
AKT/HIF-1 signaling pathway. 
In conclusion, this study for the first time 
presented evidence that AEG-1 is associated 
with hypoxia-induced HCC chemoresistance. 
Further, we revealed that the AEG-1 stimu-
lating PI3K/AKT/HIF-1/MDR-1 is under-
lying the mechanisms by which AEG-1 pro-
motes the chemoresistance. This study con-
tributes to the target therapy that overcomes 
the multidrug resistance in HCC. 
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